Summary Ruxolitinib, the cornerstone treatment for myelofibrosis, polycythemia vera, and graft-versus-host disease, just got easier to take. On May 1, 2026, the FDA approved Jakafi XR™, a once-daily extended-release tablet formulation of the same proven drug. It will be available at pharmacies as early as May 8. Key Points Same medicine, simpler schedule: Jakafi XR […]
Interferon Treatment for MPNs: What You Need to Know
by David Wallace The Big Picture If you’ve been diagnosed with a myeloproliferative neoplasm (MPN) such as polycythemia vera, essential thrombocythemia, or myelofibrosis, you’ve likely heard about interferon therapy. Keep reading to discover what current research tells us about this treatment option. What Exactly Is Interferon? Think of interferon as your body’s natural antiviral security […]
Help advance Myelofibrosis research from home
PV Reporter, in partnership with Sanguine Biosciences, is reaching out to raise awareness about an at-home research opportunity for patients diagnosed with Myelofibrosis. What is the goal of the at-home research? The goal of this research is to enhance their understanding of Myelofibrosis, in support of developing new diagnostic and treatment options for patients living […]
Fedratinib newly approved treatment for Myelofibrosis patients
Moshe Talpaz 1, Jean-Jacques Kiladjian 2 – Received: 14 February 2020 / Revised: 15 June 2020 / Accepted: 25 June 2020 © The Author(s) 2020. This article is published with open access Abstract Myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) is characterized by cytopenias, marrow fibrosis, constitutional symptoms, extramedullary hematopoiesis, splenomegaly, and shortened survival. Constitutive activation of […]
Inrebic (Fedratinib) receives FDA Approval for Myelofibrosis
The First New Treatment in Nearly a Decade for MF Patients INREBIC provides new, once-daily oral option for patients affected by rare bone marrow cancer SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or […]
